Research Analysts Issue Forecasts for CRVS FY2028 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will earn $0.11 per share for the year, down from their previous forecast of $0.14. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.44 EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price (up from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.67.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS opened at $3.38 on Thursday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The stock’s 50-day simple moving average is $4.61 and its 200-day simple moving average is $6.05. The firm has a market cap of $217.19 million, a price-to-earnings ratio of -3.63 and a beta of 0.91.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtus ETF Advisers LLC bought a new stake in Corvus Pharmaceuticals during the fourth quarter valued at $47,000. Nwam LLC bought a new position in Corvus Pharmaceuticals in the third quarter worth about $53,000. PKS Advisory Services LLC bought a new position in shares of Corvus Pharmaceuticals during the fourth quarter valued at approximately $56,000. Alpine Global Management LLC acquired a new stake in shares of Corvus Pharmaceuticals during the 4th quarter worth approximately $62,000. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Corvus Pharmaceuticals in the 4th quarter worth approximately $72,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.